Our data showed that at the 6th month of anti-TB therapy, the frequency of CD4+ T cell subpopulation was recurrently affected in DS-TB and DR-TB; moreover, TNFR2 expression is decreased on the cell surface of uTreg, actCD4+ and CD4+ T cells, suggesting that TNFR2 pathway-dependent functions could be affected, for instance, regulatory functions of inflammation. Here, CD4 is linked to tuberculosis.